AR082914A1 - Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos - Google Patents
Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismosInfo
- Publication number
- AR082914A1 AR082914A1 ARP110103259A ARP110103259A AR082914A1 AR 082914 A1 AR082914 A1 AR 082914A1 AR P110103259 A ARP110103259 A AR P110103259A AR P110103259 A ARP110103259 A AR P110103259A AR 082914 A1 AR082914 A1 AR 082914A1
- Authority
- AR
- Argentina
- Prior art keywords
- halogen
- lower alkyl
- group
- unsubstituted
- hydrogen
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical group 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000005094 alkyl carbonyl amino alkyl group Chemical group 0.000 abstract 1
- 125000005242 carbamoyl alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
A su obtención, a composiciones farmacéuticas que los contienen y a su utilización como medicamentos para el tratamiento y/o profilaxis de enfermedades que pueden tratarse con agentes que elevan el nivel del colesterol HDL, por ejemplo en especial la dislipidemia, la aterosclerosis y las enfermedades cardiovasculares.Reivindicación 1: Compuestos de la fórmula (1) en la que: A1, A2 y A3 sé eligen entre N y CH, con la condición de que por lo menos uno de A1, A2 o A3 sea N y por lo menos uno de A1, A2 o A3 sea CH; R1 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilalquilo inferior, hidroxialquilo inferior, alcoxialquilo inferior, halógeno-alquilo inferior, carbamoilalquilo inferior, alquilcarbonilaminoalquilo inferior, fenilalquilo inferior, heterociclilalquilo inferior, cuyo resto heterociclilo está sin sustituir o sustituido por oxo, heteroarilalquilo inferior, cuyo resto heteroarilo está sin sustituir o mono- o disustituido por alquilo inferior y fenilo, que está sin sustituir o mono- o disustituido por halógeno; R2 y R6 con independencia entre sí son hidrógeno o halógeno; R3 y R5 con independencia entre sí se eligen entre el grupo formado por hidrógeno, alquilo inferior, alcoxi inferior, halógeno, halógeno-alquilo inferior, halógenoalcoxi inferior y ciano; R4 se elige entre el grupo formado por hidrógeno, alcoxi inferior, halógeno, halógeno-alquilo inferior, halógenoalcoxi inferior y ciano; o R4 y R5 junto con los átomos de C a los que están unidos forman un carbociclo de cinco o seis eslabones o un heterociclo de cinco o seis eslabones que contiene uno, dos o tres heteroátomos elegidos entre el grupo formado por N, O y S, dichos carbociclo o heterociclo están sin sustituir o sustituidos por uno o dos sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, alcoxi inferior, halógeno, halógeno-alquilo inferior, halógeno-alcoxi inferior y ciano; R7 y R7’ con independencia entre sí son hidrógeno o alquilo inferior; R8 es un grupo heteroarilo de cinco o seis eslabones que contiene uno, dos o tres heteroátomos elegidos entre el grupo formado por N, O y S, dicho grupo heteroarilo está sin sustituir o sustituido por uno o dos sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, alcoxi inferior, halógeno, halógeno- alquilo inferior y cicloalquilo; y sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10175984 | 2010-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082914A1 true AR082914A1 (es) | 2013-01-16 |
Family
ID=44359517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103259A AR082914A1 (es) | 2010-09-09 | 2011-09-07 | Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8729105B2 (es) |
| EP (1) | EP2613785B1 (es) |
| JP (1) | JP5667297B2 (es) |
| KR (1) | KR101546595B1 (es) |
| CN (1) | CN103118680B (es) |
| AR (1) | AR082914A1 (es) |
| BR (1) | BR112013005622A2 (es) |
| CA (1) | CA2808665A1 (es) |
| ES (1) | ES2548035T3 (es) |
| MX (1) | MX2013002660A (es) |
| RU (1) | RU2013113118A (es) |
| TW (1) | TW201217367A (es) |
| WO (2) | WO2012031817A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL1037569C2 (en) * | 2009-12-18 | 2011-06-21 | Eurovet Animal Health B V | Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use. |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| TWI644016B (zh) * | 2012-11-02 | 2018-12-11 | 艾克頌美孚上游研究公司 | 用於在化學計量廢氣再循環氣渦輪系統中以氧化劑－稀釋劑混合進行擴散燃燒之系統及方法 |
| US9512141B2 (en) | 2012-12-07 | 2016-12-06 | Hoffmann-La Roche Inc. | Pyrazine derivatives as CB2 receptor agonists |
| RS56424B1 (sr) * | 2012-12-07 | 2018-01-31 | Hoffmann La Roche | Piridin-2-amidi korisni kao cb2-agonisti |
| CN104837831B (zh) * | 2012-12-07 | 2017-10-31 | 霍夫曼-拉罗奇有限公司 | 新的吡啶衍生物 |
| CA2885987A1 (en) * | 2012-12-07 | 2014-06-12 | F. Hoffmann-La Roche Ag | Pyridine-2-amides useful as cb2 agonists |
| SG11201608246VA (en) * | 2014-04-04 | 2016-10-28 | Hoffmann La Roche | 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists |
| MA39843A (fr) * | 2014-04-04 | 2017-02-08 | Hoffmann La Roche | Pyridine-2-amides utiles comme agonistes de cb2 |
| WO2016149324A1 (en) | 2015-03-16 | 2016-09-22 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 2 |
| AR112199A1 (es) * | 2017-06-20 | 2019-10-02 | Hoffmann La Roche | Derivados de piridina como agonistas inversos del receptor cannabinoide 2 |
| US20200085810A1 (en) | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| US20230103965A1 (en) | 2020-02-02 | 2023-04-06 | Ramot At Tel-Aviv University Ltd. | Novel activators of the lipidating transporter atp binding cassette protein type 1 (ab-ca1) and therapeutic uses thereof |
| CN113390984B (zh) * | 2021-05-31 | 2022-09-16 | 常州沃腾化工科技有限公司 | 环丁醇和环丙甲醇的气相分离分析方法 |
| US11814354B2 (en) | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
| CN120987838B (zh) * | 2025-10-22 | 2026-01-09 | 潍坊学院 | 三维网状结构钡配合物催化剂及其制备方法与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555323B2 (en) * | 2000-02-08 | 2003-04-29 | Pfizer Inc. | Assay for ABCA1 |
| SE0104332D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0222495D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| ES2326280T3 (es) * | 2005-04-06 | 2009-10-06 | F. Hoffmann-La Roche Ag | Derivados de piridin-3-carboxamida como agonistas inversos de cb1. |
| US7629346B2 (en) * | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| AU2007304365A1 (en) * | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents |
| ES2344128T3 (es) * | 2006-10-04 | 2010-08-18 | F. Hoffmann-La Roche Ag | Derivados de pirazina-2-carboxamida como moduladores de receptores cb2. |
| US8088920B2 (en) | 2008-03-31 | 2012-01-03 | Hoffmann-La Roche Inc. | 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents |
| US7897621B2 (en) * | 2008-03-31 | 2011-03-01 | Hoffmann-La Roche Inc. | 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents |
| CN102271682B (zh) * | 2008-10-31 | 2015-12-16 | 默沙东公司 | 用于治疗疼痛的p2x3受体拮抗剂 |
| UA107088C2 (xx) | 2009-09-11 | 2014-11-25 | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину | |
| US8669254B2 (en) * | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
-
2011
- 2011-07-21 WO PCT/EP2011/062548 patent/WO2012031817A1/en not_active Ceased
- 2011-09-06 ES ES11752233.4T patent/ES2548035T3/es active Active
- 2011-09-06 BR BR112013005622A patent/BR112013005622A2/pt not_active IP Right Cessation
- 2011-09-06 JP JP2013527569A patent/JP5667297B2/ja not_active Expired - Fee Related
- 2011-09-06 MX MX2013002660A patent/MX2013002660A/es active IP Right Grant
- 2011-09-06 EP EP11752233.4A patent/EP2613785B1/en not_active Not-in-force
- 2011-09-06 CN CN201180043044.7A patent/CN103118680B/zh not_active Expired - Fee Related
- 2011-09-06 KR KR1020137008925A patent/KR101546595B1/ko not_active Expired - Fee Related
- 2011-09-06 WO PCT/EP2011/065341 patent/WO2012032018A1/en not_active Ceased
- 2011-09-06 CA CA2808665A patent/CA2808665A1/en not_active Abandoned
- 2011-09-06 RU RU2013113118/04A patent/RU2013113118A/ru not_active Application Discontinuation
- 2011-09-07 AR ARP110103259A patent/AR082914A1/es not_active Application Discontinuation
- 2011-09-07 TW TW100132315A patent/TW201217367A/zh unknown
- 2011-09-07 US US13/226,521 patent/US8729105B2/en not_active Expired - Fee Related
-
2014
- 2014-02-24 US US14/187,723 patent/US9090599B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2808665A1 (en) | 2012-03-15 |
| CN103118680B (zh) | 2015-12-16 |
| TW201217367A (en) | 2012-05-01 |
| ES2548035T3 (es) | 2015-10-13 |
| EP2613785A1 (en) | 2013-07-17 |
| EP2613785B1 (en) | 2015-07-29 |
| RU2013113118A (ru) | 2014-10-20 |
| KR20130081288A (ko) | 2013-07-16 |
| JP2013537173A (ja) | 2013-09-30 |
| BR112013005622A2 (pt) | 2016-05-03 |
| WO2012032018A1 (en) | 2012-03-15 |
| US9090599B2 (en) | 2015-07-28 |
| KR101546595B1 (ko) | 2015-08-21 |
| CN103118680A (zh) | 2013-05-22 |
| HK1181655A1 (zh) | 2013-11-15 |
| US20140194436A1 (en) | 2014-07-10 |
| US20120065212A1 (en) | 2012-03-15 |
| JP5667297B2 (ja) | 2015-02-12 |
| US8729105B2 (en) | 2014-05-20 |
| MX2013002660A (es) | 2013-04-09 |
| WO2012031817A1 (en) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082914A1 (es) | Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos | |
| AR089807A1 (es) | Compuestos de imidazopirrolidinona | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| PE20200008A1 (es) | Isoquinolinas como inhibidores de hpk1 | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR079334A1 (es) | Derivados de oxazin amino | |
| EA201500557A1 (ru) | Антигельминтные соединения, композиции и способы их применения | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| RU2017105781A (ru) | Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение | |
| PE20160540A1 (es) | Inhibidores de bromodominios | |
| AR092503A1 (es) | 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b | |
| AR082886A1 (es) | Compuestos y composiciones farmaceuticas que los contienen | |
| AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
| AR085398A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| AR098492A1 (es) | Derivados de purina | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| AR084152A1 (es) | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc | |
| BR112016019462B8 (pt) | Compostos heterocïclicos tricïclicos como inibidores de fosfoinosotida 3-cinase | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| AR091261A1 (es) | Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |